Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri TbkISX:OMED +2.44%89 Debt-to-EBITDA is 0.40 as of Jun. 2026, which is 7% below its 10-year median of 0.43. GuruFocus rates ISX:OMED with a GF Score™ of 89/100 and a GF Value™ of Rp239.88 (Fairly Valued). The stock has 2 warning signs investors should review. Among 472 Medical Devices & Instruments companies, PT Jayamas Medica Industri Tbk ranks better than 74.58% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PT Jayamas Medica Industri Tbk's Debt-to-EBITDA or its related term are showing as below:
ISX:OMED'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.43 Max: 0.51
Current: 0.45
During the past 7 years, the highest Debt-to-EBITDA Ratio of PT Jayamas Medica Industri Tbk was 0.51. The lowest was 0.01. And the median was 0.43.
ISX:OMED's Debt-to-EBITDA is ranked better than 74.58% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ISX:OMED: 0.45
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PT Jayamas Medica Industri Tbk Debt-to-EBITDA Related Terms
PT Jayamas Medica Industri Tbk Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk Debt-to-EBITDA Chart
ISX:OMED vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Debt-to-EBITDA of 0.40 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Jayamas Medica Industri Tbk. This is near median its historical median of 0.43. Over the past decade, PT Jayamas Medica Industri Tbk's Debt-to-EBITDA has ranged from 0.01 to 0.51. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #120 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 25.4%.
Is PT Jayamas Medica Industri Tbk's Debt-to-EBITDA too high?
PT Jayamas Medica Industri Tbk's current Debt-to-EBITDA of 0.40 is near median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.51. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. PT Jayamas Medica Industri Tbk's value of 0.40 is 75.5% below this industry median. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #120 out of 472 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #120 out of 472 companies for Debt-to-EBITDA. This puts PT Jayamas Medica Industri Tbk in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. PT Jayamas Medica Industri Tbk's value of 0.40 is 75.5% below this benchmark. Historically, PT Jayamas Medica Industri Tbk's own Debt-to-EBITDA has ranged from 0.01 to 0.51 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 1.64, PT Jayamas Medica Industri Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Jayamas Medica Industri Tbk's current Debt-to-EBITDA of 0.40 is 75.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PT Jayamas Medica Industri Tbk. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current Debt-to-EBITDA is 0.40, which is near median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.88, compared to a current price of Rp252.00 — trading 5.1% above its estimated fair value. The current Debt-to-EBITDA is 0.40, which is near median its 10-year median of 0.43 and 75.5% below the Medical Devices & Instruments industry median of 1.64. PT Jayamas Medica Industri Tbk's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Debt-to-EBITDA is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be overvalued.
The current stock price of Rp252.00 is trading 5.1% above its estimated GF Value™ of Rp239.88.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
Debt-to-EBITDA: 0.40 (near median its 10-year median of 0.43)
GF Value™: Rp239.88 vs. price of Rp252.00 (5.1% above fair value)
Industry Position: 75.5% below the Medical Devices & Instruments median (#120 of 472)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
89GF Score
Get the complete analysis for ISX:OMED
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
